S&P 500   4,964.29 (-0.23%)
DOW   38,502.21 (-0.16%)
QQQ   423.68 (-0.85%)
AAPL   181.39 (-0.09%)
MSFT   399.58 (-0.80%)
META   467.11 (-0.88%)
GOOGL   142.15 (+0.73%)
AMZN   167.85 (+0.46%)
TSLA   193.21 (-0.28%)
NVDA   672.06 (-3.23%)
NIO   6.03 (+1.17%)
AMD   163.47 (-1.34%)
BABA   75.73 (+3.54%)
T   16.94 (+0.18%)
F   12.08 (-1.39%)
MU   80.50 (-0.26%)
CGC   3.34 (-5.65%)
GE   148.53 (-0.06%)
DIS   107.73 (-1.56%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.79 (-1.43%)
XOM   104.56 (+1.76%)
S&P 500   4,964.29 (-0.23%)
DOW   38,502.21 (-0.16%)
QQQ   423.68 (-0.85%)
AAPL   181.39 (-0.09%)
MSFT   399.58 (-0.80%)
META   467.11 (-0.88%)
GOOGL   142.15 (+0.73%)
AMZN   167.85 (+0.46%)
TSLA   193.21 (-0.28%)
NVDA   672.06 (-3.23%)
NIO   6.03 (+1.17%)
AMD   163.47 (-1.34%)
BABA   75.73 (+3.54%)
T   16.94 (+0.18%)
F   12.08 (-1.39%)
MU   80.50 (-0.26%)
CGC   3.34 (-5.65%)
GE   148.53 (-0.06%)
DIS   107.73 (-1.56%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.79 (-1.43%)
XOM   104.56 (+1.76%)
S&P 500   4,964.29 (-0.23%)
DOW   38,502.21 (-0.16%)
QQQ   423.68 (-0.85%)
AAPL   181.39 (-0.09%)
MSFT   399.58 (-0.80%)
META   467.11 (-0.88%)
GOOGL   142.15 (+0.73%)
AMZN   167.85 (+0.46%)
TSLA   193.21 (-0.28%)
NVDA   672.06 (-3.23%)
NIO   6.03 (+1.17%)
AMD   163.47 (-1.34%)
BABA   75.73 (+3.54%)
T   16.94 (+0.18%)
F   12.08 (-1.39%)
MU   80.50 (-0.26%)
CGC   3.34 (-5.65%)
GE   148.53 (-0.06%)
DIS   107.73 (-1.56%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.79 (-1.43%)
XOM   104.56 (+1.76%)
S&P 500   4,964.29 (-0.23%)
DOW   38,502.21 (-0.16%)
QQQ   423.68 (-0.85%)
AAPL   181.39 (-0.09%)
MSFT   399.58 (-0.80%)
META   467.11 (-0.88%)
GOOGL   142.15 (+0.73%)
AMZN   167.85 (+0.46%)
TSLA   193.21 (-0.28%)
NVDA   672.06 (-3.23%)
NIO   6.03 (+1.17%)
AMD   163.47 (-1.34%)
BABA   75.73 (+3.54%)
T   16.94 (+0.18%)
F   12.08 (-1.39%)
MU   80.50 (-0.26%)
CGC   3.34 (-5.65%)
GE   148.53 (-0.06%)
DIS   107.73 (-1.56%)
AMC   4.57 (-1.93%)
PFE   27.47 (-0.43%)
PYPL   57.79 (-1.43%)
XOM   104.56 (+1.76%)
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

$179.37
-1.29 (-0.71%)
(As of 12:45 PM ET)
Today's Range
$178.64
$180.83
50-Day Range
$165.79
$193.66
52-Week Range
$132.24
$243.52
Volume
244,792 shs
Average Volume
903,947 shs
Market Capitalization
$26.38 billion
P/E Ratio
29.65
Dividend Yield
1.07%
Price Target
$196.30

ResMed MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
9.4% Upside
$196.30 Price Target
Short Interest
Bearish
4.30% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-0.68
Upright™ Environmental Score
News Sentiment
1.19mentions of ResMed in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$457,860 Sold Last Quarter
Proj. Earnings Growth
10.96%
From $7.39 to $8.20 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.87 out of 5 stars

Medical Sector

49th out of 1,856 stocks

Surgical & Medical Instruments Industry

3rd out of 190 stocks


RMD stock logo

About ResMed Stock (NYSE:RMD)

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

RMD Stock Price History

RMD Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Resmed Inc.
How high could the ResMed share price climb?
RMD Dec 2024 210.000 put
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Decoding ResMed Inc (RMD): A Strategic SWOT Insight
Here's Why ResMed (RMD) is a Strong Momentum Stock
ResMed stock jumps after Q2 earnings beat
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
Why ResMed Is One Of My Top Picks In 2024
Here's Why ResMed (RMD) is a Strong Growth Stock
ResMed: A Buy For Investors Seeking Long-Term Rewards
ResMed: Putting GLP-1 Myths To Sleep
See More Headlines
Receive RMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 12/14 Dividend
11/08/2023
Dividend Payable
12/14/2023
Last Earnings
1/24/2024
Ex-Dividend for 3/14 Dividend
2/07/2024
Today
2/21/2024
Dividend Payable
3/14/2024
Next Earnings (Estimated)
4/25/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
10,140
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$196.30
High Stock Price Target
$230.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+8.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$897.56 million
Pretax Margin
24.37%

Debt

Sales & Book Value

Annual Sales
$4.22 billion
Cash Flow
$7.82 per share
Book Value
$30.47 per share

Miscellaneous

Free Float
145,309,000
Market Cap
$26.57 billion
Optionable
Optionable
Beta
0.69

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of ResMed was last updated on Monday, February 19, 2024 at 9:32 PM.














RMD Stock Analysis - Frequently Asked Questions

Should I buy or sell ResMed stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RMD shares.
View RMD analyst ratings
or view top-rated stocks.

What is ResMed's stock price target for 2024?

10 Wall Street research analysts have issued 12 month target prices for ResMed's shares. Their RMD share price targets range from $165.00 to $230.00. On average, they expect the company's stock price to reach $196.30 in the next twelve months. This suggests a possible upside of 9.4% from the stock's current price.
View analysts price targets for RMD
or view top-rated stocks among Wall Street analysts.

How have RMD shares performed in 2024?

ResMed's stock was trading at $172.02 at the beginning of 2024. Since then, RMD stock has increased by 4.3% and is now trading at $179.45.
View the best growth stocks for 2024 here
.

Are investors shorting ResMed?

ResMed saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 6,330,000 shares, an increase of 7.5% from the January 15th total of 5,890,000 shares. Based on an average daily volume of 969,700 shares, the days-to-cover ratio is presently 6.5 days.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our RMD earnings forecast
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Wednesday, January, 24th. The medical equipment provider reported $1.88 EPS for the quarter, beating the consensus estimate of $1.81 by $0.07. The medical equipment provider had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.15 billion. ResMed had a net margin of 19.77% and a trailing twelve-month return on equity of 23.86%. ResMed's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.66 EPS.
Read the conference call transcript
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Wednesday, January 24th. Investors of record on Thursday, February 8th will be given a dividend of $0.48 per share on Thursday, March 14th. This represents a $1.92 annualized dividend and a dividend yield of 1.07%. The ex-dividend date of this dividend is Wednesday, February 7th.
Read our dividend analysis for RMD
.

Is ResMed a good dividend stock?

ResMed (NYSE:RMD) pays an annual dividend of $1.92 per share and currently has a dividend yield of 1.06%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 31.74%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RMD will have a dividend payout ratio of 23.41% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RMD.

What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed Chief Executive Officer Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among the company's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

Who are ResMed's major shareholders?

ResMed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (12.06%), Northern Trust Corp (0.99%), Norges Bank (0.92%), Legal & General Group Plc (0.76%), Charles Schwab Investment Management Inc. (0.59%) and FIL Ltd (0.57%). Insiders that own company stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Karen Drexler, Kaushik Ghoshal, Lucile Blaise, Michael J Farrell, Michael J Rider, Peter C Farrell, Rajwant Sodhi and Robert Andrew Douglas.
View institutional ownership trends
.

How do I buy shares of ResMed?

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ResMed have any subsidiaries?
The following companies are subsidiares of ResMed: Matrixcare, and Propeller Health.
Read More
This page (NYSE:RMD) was last updated on 2/21/2024 by MarketBeat.com Staff